- Home
- BE vs RNA Comparison
BE vs RNA Comparison
Compare BE & RNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BE
- RNA
- Stock Information
- Founded
- BE 2001
- RNA 2012
- Country
- BE United States
- RNA United States
- Employees
- BE N/A
- RNA N/A
- Industry
- BE Industrial Machinery/Components
- RNA Biotechnology: Pharmaceutical Preparations
- Sector
- BE Energy
- RNA Health Care
- Exchange
- BE Nasdaq
- RNA Nasdaq
- Market Cap
- BE 5.1B
- RNA 4.0B
- IPO Year
- BE 2018
- RNA 2020
- Fundamental
- Price
- BE $57.08
- RNA $50.36
- Analyst Decision
- BE Buy
- RNA Strong Buy
- Analyst Count
- BE 17
- RNA 14
- Target Price
- BE $29.26
- RNA $69.50
- AVG Volume (30 Days)
- BE 10.5M
- RNA 2.6M
- Earning Date
- BE 11-06-2025
- RNA 11-06-2025
- Dividend Yield
- BE N/A
- RNA N/A
- EPS Growth
- BE N/A
- RNA N/A
- EPS
- BE 0.10
- RNA N/A
- Revenue
- BE $1,630,054,000.00
- RNA $10,729,000.00
- Revenue This Year
- BE $22.74
- RNA N/A
- Revenue Next Year
- BE $21.12
- RNA $110.16
- P/E Ratio
- BE $564.64
- RNA N/A
- Revenue Growth
- BE 22.72
- RNA 1.23
- 52 Week Low
- BE $9.02
- RNA $21.51
- 52 Week High
- BE $57.33
- RNA $56.00
- Technical
- Relative Strength Index (RSI)
- BE 77.23
- RNA 70.61
- Support Level
- BE $48.87
- RNA $45.24
- Resistance Level
- BE $55.07
- RNA $49.76
- Average True Range (ATR)
- BE 2.95
- RNA 2.14
- MACD
- BE 0.29
- RNA -0.09
- Stochastic Oscillator
- BE 98.63
- RNA 88.19
About BE Bloom Energy Corporation
Bloom Energy designs, manufactures, sells, and installs solid-oxide fuel cell systems ("Energy Servers") for on-site power generation. Bloom Energy Servers are fuel-flexible and can use natural gas, biogas, and hydrogen to create 24/7 electricity for stationary applications. In 2021, the company announced plans to leverage its technology and enter the electrolyzer market. Bloom primarily sells its systems in the United States and internationally.
About RNA Avidity Biosciences Inc.
Avidity Biosciences Inc is a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, or AOCs. Company's pipeline currently has three programs in potentially registrational clinical trials: DM1, FSHD, and DMD. The segments includes following: Del-zota for DMD44, Del-desiran for DM1, Del-brax for FSHD.